These findings support that P2Y12 inhibitor monotherapy is a feasible, alternative choice of medical treatment for patients with or without diabetes mellitus undergoing percutaneous intervention with stent implantation in the modern era. This evidence concerns the gene P2RY12 and diabetes mellitus.